Alzheimer therapeutics - What after the cholinesterase inhibitors?

Age and Ageing

Volumn 35, Issue 4, 2006, Pages 332-335

  Walker, Lary C ^a,b   Rosen, Rebecca F ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLURBIPROFEN; GALANTAMINE; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; LEVO FLURBIPROFEN; MEMANTINE; NOOTROPIC AGENT; RIVASTIGMINE; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CATABOLISM; CLINICAL TRIAL; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG TARGETING; HUMAN; IMMUNIZATION; MENINGOENCEPHALITIS; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN SYNTHESIS INHIBITION; SENILE PLAQUE;

ACETYLCHOLINE; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; NEUROLOGY;

EID: 33745376808     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afl009     Document Type: Article

References (40)

1. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163: 495-529.
2. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003; 2: 539-47.
3. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does Donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005; 162: 676-82.
4. Koch HJ, Uyanik G, Fischer-Barnicol D. Memantine: A therapeutic approach in treating Alzheimer's and vascular dementia. Curr Drug Targets CNS Neurol Disord 2005; 4: 499-506.
5. Mayor S. NICE recommends drugs for moderate Alzheimer's disease. BMJ 2006; 332: 195.
6. Bick KL. The early story of Alzheimer disease. In: Terry RD, Katzman R, Bick KL, Sisodia SS, eds. Alzheimer Disease. Philadelphia: Lippincott Williams and Wilkins, 1999, 1-9.
7. Walker LC, LeVine H III. Proteopathy: The next therapeutic frontier? Curr Opin Investig Drugs 2002; 3: 782-7.
8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
9. Giannakopoulus P, Herrmann FR, Bussiere T et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60: 1495-500.
10. Lau LF, Schachter JB, Seymour PA, Sanner MA. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. Curr Top Med Chem 2002; 2: 395-415.
11. Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 2005; 1739: 240-50.
12. Klein WL. Aβ toxicity in Alzheimer's disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002; 41: 345-52.
13. Walsh DM, Selkoe DJ. Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004; 11: 213-28.
14. Maiorini AF, Gaunt MJ, Jacobsen TM, McKay AE, Waldman LD, Raffa RB. Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. J Clin Pharm Ther 2002; 27: 169-83.
15. Singer O, Marr RA, Rockenstein E et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005; 8: 1343-9.
16. Brunkan AL, Goate AM. Presenilin function and gammasecretase activity. J Neurochem 2005; 93: 769-92.
17. Pollack SJ, Lewis H. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 2005; 6: 35-47.
18. Eriksen JL, Saji SA, Smith TE et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112: 440-9.
19. Black SE, Wilcock G, Haworth J et al. A placebo-controlled, double-blind trial of the selective Aβ42-lowering agent, Flurizan in patients with mild to moderate Alzheimer's disease: Efficacy, safety, and follow-up study results. Presentation at the 35th Annual Meeting of the Society for Neuroscience (Program Number 586.6), 15 November 2005, Washington, DC.
20. Lanz TA, Fici GJ, Merchant KM. Lack of specific amyloidbeta (1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther 2005; 312: 399-406.
21. Kornacker MG, Lai Z, Witmer M et al. An inhibitor binding pocket distinct from the catalytic active site on human β-APP cleaving enzyme. Biochemistry 2005; 44: 11567-73.
22. Lichtenthaler SF, Haass C. Amyloid at the cutting edge: Activation of α-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J Clin Invest 2004; 113: 1384-7.
23. Parvathy S, Ehrlich M, Pedrini S et al. Atorvastatin-induced activation of Alzheimer's α-secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J Neurochem 2004; 90: 1005-10.
24. Mason JM, Kokkoni N, Stott K, Doig AJ. Design strategies for anti-amyloid agents. Curr Opin Struct Biol 2003; 13: 526-32.
25. Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease: From secretase modulators to polymerization inhibitors. CNS Drugs 2005; 19: 989-96.
26. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Aβ peptide: The many roads to perdition. Neuron 2004; 43: 605-8.
27. Leissring MA, Farris W, Chang AY et al. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003; 40: 1087-93.
28. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005; 45: 675-88.
29. Hock C, Konietzko U, Streffer JR et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-54.
30. Gilman S, Koller M, Black RS et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-62.
31. Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003; 61: 46-54.
32. Zerbinatti CP, Bu G. LRP and Alzheimer's disease. Rev Neurosci 2005; 16: 123-35.
33. Lam FC, Liu R, Lu P et al. β-Amyloid efflux mediated by p-glycoprotein. J Neurochem 2001; 76: 1121-8.
34. Vogelgesang S, Warzok RW, Cascorbi I et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2004; 1: 121-5.
35. Cirrito JR, Deane R, Fagan AM et al. P-Glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Invest 2005; 115: 3285-90.
36. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005; 280: 17294-300.
37. Quist A, Doudevski I, Lin H et al. Amyloid ion channels: A common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 2005; 102: 10427-32.
38. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals and amyloid-β in Alzheimer's disease. Int J Exp Pathol 2005; 86: 147-59.
39. Moreira PI, Honda K, Liu Q et al. Oxidative stress: The old enemy in Alzheimer's disease pathophysiology. Curr Alzheimer Res 2005; 2: 403-8.
40. Rozemuller AJ, van Gool WA, Eikelenboom P. The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer's disease: therapeutic implications. Curr Drug Targets CNS Neurol Disord 2005; 4: 223-33.